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ABSTRACT
Characterization of Pro-inflammatory and Anti-inflammatory Microglia in the Anterior
Cingulate Cortex in Autism Spectrum Disorder
by
Aubrey N. Sciara

Autism spectrum disorder (ASD) is associated with functional abnormalities of the anterior
cingulate cortex (ACC), a brain area that mediates social behavior. Given evidence of a role of
inflammation in ASD, markers of pro-inflammatory and anti-inflammatory microglia were
studied using postmortem ACC tissues from ASD and age-matched typically developed control
donors. Gene expression levels of pro-inflammatory (CD68, HLA-DRA, IL1B, NOS2, PTGS2)
and anti-inflammatory (ARG1, IGF1, MRC1, PPARG) microglial genes were measured using
quantitative real-time PCR. Additionally, brain sections were immunohistochemically stained
for a microglial marker. Expression levels of IGF1 were modestly higher, while the expression
of MRC1 was modestly lower in ASD donors when compared to control donors. No other
differences in gene expression levels between the two groups of donors were observed.
Statistical significance for changes in expression levels IGF1 and MRC1 did not survive
correction for multiple comparisons. Further research on anti-inflammatory microglial
involvement in ASD is warranted.
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CHAPTER 1
INTRODUCTION
Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a collection of disorders that encompasses
neurodevelopmental disorders such as Autistic Disorder, Asperger Syndrome, and Pervasive
Developmental Disorder-Not Otherwise Specified. ASD is associated with deficits in an
individual’s language and speech, social interaction, and/or motor function. Since the first
epidemiological survey in 1966, the prevalence of autism has increased from 1 in 2,000
individuals to approximately 1 in 160 individuals globally (World Health Organization 2013). In
the United States, it affects 1 in 68 children with a male to female ratio of 5:1 (Baio 2014). It is
argued that improved diagnostic tools and increased awareness of ASD in the last 50 years have
had an effect on the increase in ASD prevalence (Vargas et al. 2005; Wing et al. 2011).
The median age of ASD diagnosis is approximately 4.5 years, even though it is possible
for a child to be diagnosed as early as the age of 2 (Baio 2014). There are a variety of tools used
to diagnose ASD; however, access to these tools still remains a challenge to low income
countries. The detection of ASD in the adult population proves to be more difficult than
diagnoses of children because it requires alternative diagnostic tools. Early diagnosis of ASD
allows for increased time to develop routines and assist in behavioral management of the
individual (World Health Organization 2013).
With such a high occurrence rate, the cost of treating and assisting autistic individuals in
the United States is astronomical. Diagnosis usually comes early in life and can bring life-long
costs. Moreover, if the individual has intellectual disabilities, the cost of care increases because
of the need for additional services. No current treatments or pathognomonic markers for ASD
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are known to exist currently, vastly increasing the need to understand ASD neuropathology. A
thorough understanding of the pathobiology of this disorder also has the potential to contribute to
the development of advanced diagnostic tools that could lead to more precise diagnoses.
As a spectrum disorder, the behavioral phenotype of individuals diagnosed with ASD is
variable and is often further differentiated. Autistic Disorder is defined by these specific deficits:
repetitive motor behavior, impaired social interaction, decreased intellectual ability, and
compromised verbal communication skills. Conversely, individuals with Asperger Syndrome
have normal language skills and those with Pervasive Developmental Disorder-Not Otherwise
Specified have some, but not all of the deficits required for an autism diagnosis (Bill and
Geschwind, 2009). It is been proposed that Asperger Syndrome and Pervasive Developmental
Disorder-Not Otherwise Specified are less severe forms of Autistic Disorder, even though a clear
distinction between the subtypes is sometimes difficult to make, partially due to the lack of
biological markers (Worley and Matson 2012). Current revisions to the diagnostic criteria, now
DSM-V, have removed these subgroups and have categorized Autistic Disorder, Asperger
Syndrome, and Pervasive Developmental Disorder-Not Otherwise Specified as ASD (reviewed
by Kim, 2015).

Etiology
Throughout the past century, scientists have debated about the etiology of ASD from two
distinct perspectives: (1) ASD is caused by a genetic mutation or abnormality or (2) that ASD is
the product of exposure to particular environmental elements. The true pathophysiology of ASD
remains unknown, keeping scientists searching for answers. Recent research has provided data
supporting both viewpoints, leading the scientific community to conclude that the etiology of
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ASD is likely the product of a combination of genetic abnormalities and exposure to some yet
unknown environmental insult.
Studies performed on identical and fraternal twins reveal a syndromic link to ASD (Bill
and Geschwind, 2009). More recently, research shows that gene mutations contribute to
approximately 55% of ASD cases (Hallmayer et al. 2011). Currently, there are 25+ loci that are
considered autism susceptibility candidate genes. Additionally, there are rare Mendelian
mutations specific to ASD such as a de novo (not in parents) copy number variation (CNV) that
are being intensely investigated (Bill and Geschwind, 2009). In contrast to single nucleotide
polymorphisms (SNPs), a change in one nucleotide in the DNA, CNV is a type of change in the
genome that results in the deletion or duplication of a genomic region that is greater than 1,000
nucleotides (Sebat et al. 2007; Geschwind 2008).
Approximately 35% of children diagnosed with ASD have a recognized genetic disorder
or a distinguishable chromosomal duplication or deletion. Many of the recognized genetic
syndromes associated with ASD originate from single gene mutations linked to the mammalian
target of rapamycin (mTOR) pathway, such as Rett’s syndrome, fragile X mental retardation 1
(FMR1), and tuberous sclerosis complex (TSC1/2) (McFadden and Minshew, 2013). The mTOR
pathway functions as a regulator of cell development, proliferation, and survival. Many
components of the pathway are located near neuronal synapses where they mediate
synaptogenesis by regulating the morphology of dendritic spines and synaptic protein synthesis.
Mutations in individuals with FMR1, TSC1/2, and other disorders such as neurofibromatosis 1
(NFM1) and phosphatase and tensin homolog (PTEN) have been found to lead to an overactive
mTOR signaling pathway (reviewed by Sawicka and Zukin 2012). Specifically, in FMR1, the
upregulated mTOR pathway results in an increase of cap-dependent protein translation. Mice

14

studies have shown that when there is an increase in the components of the cap-dependent
translation initiation complex, the mice display enhanced repetitive behavior (Huber et al. 2015).
Based off of the role the mTOR pathway plays in other ASD-like disorders, it has been
suggested that persons with ASD may have an irregular mTOR pathway as well (reviewed by
Sawicka and Zukin 2012). Although Rett’s syndrome, FMR1, and TSC1/2 are associated with
ASD, the pathophysiology of each disorder stems from a different genetic abnormality (reviewed
by Strathearn, 2009). Because genetic abnormalities do not account for 100% of the cause, it is
speculated that in addition to specific gene mutations, environmental risk factors, increased ages
of parents, and a general lack of parental nurture may be correlated with an increased risk for
ASD (Durkin et al. 2008; Strathearn 2009; World Health Organization 2013).
Additionally, studies have suggested that maternal autoimmune disorders and various
teratogens may play a role in the pathogenesis of ASD (Strömland et al. 1994; Atladóttir et al.
2009; Keil et al. 2010; reviewed by Dufour-Rainfray et al. 2011; Stevens et al. 2013; Chen et al.
2016). A Danish study of 3325 children who had been diagnosed with ASD showed an
increased risk when the mother had a history of an autoimmune disorder such as celiac disease or
rheumatoid arthritis. The researchers also concluded that there is a potential genetic link
between maternal and/or paternal type 1 diabetes (T1D) based on the parental history of T1D and
the number children with ASD (Atladóttir et al. 2009). Epidemiological studies have also
reported a correlation between the exposure of a fetus to teratogens such as valproic acid
(antiepileptic drug), thalidomide (sedative), and misoprostol (drug for gastric ulcers) and a
diagnosis of ASD (reviewed by Dufour-Rainfray et al. 2011). Furthermore, ethanol consumption
by pregnant women not only causes abnormalities in the child such as fetal alcohol syndrome,
but researchers are hypothesizing it may have teratogenic effects on cellular regulation and may
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cause abnormal gene expression via epigenetic modifications. Researchers are currently
attempting to determine what effect exposure time has on these teratogenic defects (reviewed by
Dufour-Rainfray et al. 2011). While these studies do not encompass all of the components of the
pathophysiology of the disorder, they do show the complexity of the etiology of ASD.

Anterior Cingulate Cortex and ASD
The central nervous system is composed of: gray matter, where neuronal cell bodies and
glia are located, and white matter, which houses primarily neuronal axons and glia. In the gray
matter, information is processed from stimuli and signals are transmitted through short- and
long-range neuronal axons. Gray matter in the cerebral cortex envelops the brain in sulci and
gyri, while white matter is immediately adjacent to the inner layer of the cortex. Specialized
cells in white matter, oligodendrocytes, provide insulation for neuronal axons that pass through
the area, facilitating the transmission of signals along axons. Microglial cells and macroglial
cells (including oligodendrocytes and astrocytes) are abundantly present in the white matter,
while there are very few neuronal cell bodies found in white matter. Divided into two
hemispheres, four lobes, the spinal cord, and complex brain areas, the central nervous system is
able to rapidly communicate between areas of different functions via the transmission of signals
through neurons, ultimately sending information to each region of the body.
The cingulate cortex is located in the medial portion of the cerebral hemispheres and is a
part of the limbic system, making it a major component in emotional processes. The cingulate
cortex is divided into two sections: the anterior cingulate cortex (ACC) and the posterior
cingulate cortex (Vogt et al. 1992; Know your Brain 2015). It is primarily hypothesized that the
cingulate cortex, as a whole, processes cognitive and emotional, sensory, and motor information

16

(reviewed by Bush, Luu, & Posner, 2000). Secondly, the cingulate cortex assimilates
information from different networks including motivation, cognition, emotion, and evaluation of
error. The anterior cingulate cortex, also referred to as Brodmann area 24 (BA24), has been
recognized as a brain area that displays abnormalities in individuals with ASD. The ACC
subserves many behavioral functions, demonstrated in studies using neuroimaging and electrical
recordings, and influences activity in other various brain regions to regulate endocrine, motor,
cognitive, and visceral responses (reviewed by Bush, Luu, & Posner, 2000). Differentiated into
many distinct sub-regions, the ACC assists in tasks that range from basic to complex. During
complex tasks, the ACC becomes activated in combination with the prefrontal cortex, suggesting
that it is essential in higher-order thinking (Margulies et al. 2007).
A meta-analysis, including 21 research publications, reported that the ACC is a brain area
that demonstrates abnormalities in individuals with ASD (DeRamus and Kana 2015). MRI
comparisons revealed decreased ACC gray matter volume in ASD individuals when compared to
typically developed controls (Greimel et al. 2013). Several studies have utilized functional
magnetic resonance imaging (fMRI), useful for the inspection of neural structures, to
demonstrate decreased synchronization of critical cortical regions during complex task
performance when comparing individuals with ASD to typically developed control subjects.
This functional decrease was specifically localized to connectivity between the frontal (anterior
cingulate and other prefrontal cortices) and more posterior cortical regions (reviewed by
McFadden and Minshew, 2013). Additionally, fMRI studies have demonstrated hypoactivation
of the ACC during visual stimulation, attentional and cognitive processing, and during social
response tasks in ASD subjects (reviewed by Gomot et al. 2006; Silk et al. 2006; Kohls et al.
2013; Urbain et al. 2015). A separate meta-analysis of 24 studies examining social processes
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concluded that there was hypoactivation in the perigenual ACC of ASD subjects solely during
social tasks (Di Martino et al. 2009). While the meta analyses and fMRI studies agree,
inconsistences in methods, analyses, and subject criteria (i.e. only subjects with Asperger’s
syndrome, inclusion of subjects on medications, or comorbidities), make it challenging to
compare the findings of these studies (Dichter et al. 2009). It is likely that the subjects of some
ASD studies are mostly individuals with moderate- to highly-functional ASD, potentially
excluding the individuals with severe ASD who lack verbal skills, whose disruptive behaviors
prevent participation, and those who are unable to interact with researchers. The exclusion of
these individuals would depend on the type of analysis performed. From this, it is simple to see
how difficult it can be to obtain reliable results from ASD studies.
Mainly, imaging methods demonstrating disruption of the function of the anterior
cingulate cortex in ASD are interpreted as gray matter deficits; however, white matter deficits
have also been implicated in ASD. White matter pathology is typically examined in vivo by
diffusion tensor imaging, a technique that measures the amount of diffusion throughout the brain
matter. Under normal conditions in the brain, white matter is less permissive of the diffusion of
water in comparison to gray matter. In ASD subjects, increased diffusion of water through the
white matter has been detected in comparison to control subjects, leading researchers to
hypothesize that ASD brains have surplus interstitial space in white matter (Groen et al. 2011).
Several studies have indicated an increase in white matter volume and a decrease in the structural
integrity of white matter in individuals with ASD, abnormalities that may contribute to motor
impairment and disruption in cognitive processing in ASD (Noriuchi et al. 2010; Groen et al.
2011; Ingalhalikar et al. 2011). White matter pathology, as indicated in these imaging studies,
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implies that cells found in the white matter are abnormal and/or there are structural changes in
neuronal axons coursing through white matter.
Thus far, most of the published research on the cellular pathology of ASD has focused on
neurons. Previously, we investigated the possible role of macroglia in white matter ASD
pathology and abnormal gene expression changes of macroglial markers MOG and GFAP
(Crawford et al. 2015). Other researchers have hypothesized that microglia play a role in the
pathophysiology of ASD (reviewed by Takano 2015). Microglia are of particular interest
because they are the immune cell of the CNS and play a role in synaptic maturation during
development. It has been reported that children with ASD suffer from chronic
neuroinflammation, which could potentially lead to neuronal cell death and a loss of synaptic
connections from upregulated inflammatory mediators (reviewed by Pardo et al. 2005;
Zimmerman et al. 2005; reviewed by Rodriguez and Kern 2011). In addition to a possible link
between inflammation in the CNS and neural network deficits, Vargas and coworkers found that
microglia are consistently activated, suggesting microglia are continually working to protect the
CNS from injury or threat of damage, in all brain regions in ASD subjects (Vargas et al. 2005;
reviewed by Edmonson et al. 2016). The microglial responses in ASD individuals were
comparable to responses seen in other neurodegenerative disorders, such as Parkinson’s disease
and Alzheimer’s disease (Vargas et al. 2005). Suzuki and coworkers found evidence of
microglia involvement in ASD, reporting an increase in a microglial binding ligand in multiple
brain regions including the ACC in young adults with ASD (Suzuki et al. 2013). These early
findings support the investigation of the alleged role of microglia in the ACC in ASD pathology.
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Microglia
In addition to the evidence supporting microglia’s possible role in white matter pathology
in ASD, microglia have been linked to autism through various other mechanisms. Located
throughout the brain and spinal cord, microglial cells are responsible for immune system and
central nervous system (CNS) protection against pathogenic factors (reviewed by Saijo & Glass,
2011). Microglia, the macrophages of the CNS, originate in the yolk-sac, arising from
erythromyeloid progenitors (EMPs), and migrate to the brain during early fetal development
(reviewed by Casano & Peri, 2015; Saijo & Glass, 2011). In contrast, neurons and macroglia
originate from the neuroectoderm (Eglitis and Mezey 1997; Glees 2005).

Forms
Ramified. Structured similarly to astrocytes, each microglial cell has multiple branching
processes that extend in all directions. In the ramified state, also termed the ‘resting’ or
‘inactivated’ form, these microglial branches continuously survey their surroundings in the CNS
and have temporary contact with local synaptic structures (reviewed by Saijo & Glass, 2011;
Tremblay, Lowery, & Majewska, 2010). Ramified microglia represent the quickest moving
structures in the brain with an average velocity of 5.44 ± 2.33 µm/min. The rapid velocity of
microglial processes allow for swift surveillance and immediate detection of injury and the
initiation of an active response, eventually prompting complete microglial activation (Lee et al.
2008).

Activated. When injury or the threat of damage to the CNS is present, ramified microglia are
able to rapidly modify their morphology, function, and gene expression to provide protection.
20

This highly regulated progression of alteration is defined as microglial activation. The once
extended branching processes retract, giving the cell the appearance of an amoeba. With the
microglia no longer focused on surveillance, they promptly migrate to the site of infection or
injury via chemotactic gradients (reviewed by Kettenmann et al. 2011).

General Functions
During early CNS development and in adulthood, microglia function as the “maid,”
removing accumulating apoptotic neurons and reducing inflammation. Microglia are also
involved in the creation of synapses in the postnatal brain, a process termed synaptogenesis. In
the adult brain, microglia serve as the “guards,” ready to protect, as well as the homeostatic
regulators of the CNS (reviewed by Kettenmann et al. 2011). Abnormalities detected in nearby
neuronal synapses initiate synaptic remodeling by microglia, which is necessary for maturation
and homeostasis. During the removal of damaged synapses, microglia release cytokines,
reactive oxygen species (ROS), and growth factors (Kettenmann et al. 2013). The phagocytic
and synaptic pruning abilities of microglia are suggested to be imperative for normal brain
development and neurogenesis (reviewed by Saijo & Glass, 2011). In transgenic mice models,
when a microglia-expressed chemokine receptor gene was knocked out, microglia were found in
reduced cell density when compared to wild-type mice. In addition to decreased microglial
density, reduced synaptic pruning and circuit maturation was observed. These changes in the
knockout mice suggest that alterations were due to decreased microglial activity (Paolicelli et al.
2011).
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Apoptotic Signaling
A study by Sieger et al., using transgenic calcium reporter zebrafish, has helped
researchers understand the mechanism by which microglia are precisely-guided to areas of
apoptotic neurons. Targeted laser ablations of neurons were performed in the brains of the
zebrafish and rapid Ca2+ gradient waves were established around the ablation site. Sieger et. al.
determined that through a possible ATP gradient created by Ca2+ signaling, microglia were being
guided to specific apoptotic neuronal sites (Sieger et al. 2012). Additionally, reversible exposure
of phosphatidylserine on the surface of neurons is stimulated by an increase in Ca2+ or the release
of ROS by lipopolysaccharides (LPS) from activated microglia (Neher et al. 2011; Brown and
Neher 2012). Chemotactic signals released by apoptotic neurons and exposed
phosphatidylserine residues on the neuronal surface are indicative of phagocytic readiness for
microglia (reviewed by Casano & Peri, 2015).
Microglia mainly phagocytize apoptotic neurons in order to promote a reduction of
inflammation and synaptic remodeling. Conversely, cells that are not undergoing apoptosis can
also be phagocytized by microglia. Phosphatidylserine, normally found on the inside of healthy
cells, can also be exposed on the surface of viable neurons if they become stressed. The
exposure of phosphatidylserine is recognized by microglia and can result in the phagocytosis of
the viable neuron. This response by microglia is considered primary phagocytosis, while
secondary phagocytosis would follow apoptosis or necrosis, and has been coined ‘phagoptosis’
(Brown and Neher 2012). The potential effects of phagoptosis in a chronically inflamed brain
area suggest that the abnormal phagocytosis of viable neurons by microglia may contribute to
neurodegeneration and subsequent disease.
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Activation Pathways
When the CNS undergoes a damaging event, microglia are immediate responders to the
site of damage. Comparable to a macrophage response outside of the CNS, microglia may be
activated through two distinct pathways, which are just beginning to be characterized in the
literature (Shechter et al. 2013). Microglia can demonstrate a pro-inflammatory (M1) phenotype,
otherwise known as the “classically activated” phenotype. Activated by interferon gamma
(IFNϒ) and toll-like receptors, pro-inflammatory microglial cells produce cytokines and assume
phagocytic roles that promote defense mechanisms and digest neurons. Conversely, the antiinflammatory (M2) microglial phenotype is also referred to as “alternatively activated”
microglia. M2 microglia are mainly activated in the presence of IL-4 and facilitate CNS healing
by participating in phagocytosis, neuronal remodeling, and tissue regeneration (Table 1)
(Gordon 2003; Arnold et al. 2007; Kigerl et al. 2009).
A signaling pathway directs information from the cellular surface of the inactivated
microglial cell to its nucleus, where specific genes are activated that determine the resulting
activated phenotype of the cell. The main difference in phenotypes that can occur is dependent
on the isoform of galectin that interacts with the microglial cell. For differentiation to the M1
phenotype, galectin-3 is released by activated microglia, binds, and activates the microglial tolllike receptor 4 (TLR4). This activation creates a chain of further pro-inflammatory microglial
activation (Burguillos et al. 2015). Conversely, the binding of galectin-1 to CD45 on the
microglial surface inhibits the production of pro-inflammatory mediators, upregulating the antiinflammatory phenotype through modulation of the CREB, NF-ᴋB, and p38-MAPK pathways
(Starossom et al. 2012). Additionally, the transcription of distinct pro-inflammatory or antiinflammatory markers have been found to be regulated by second messengers, such as cAMP
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and Ca2+, and miRNAs, that can promote one phenotype by downregulating the expression of the
other (Schebesch et al. 1997; Martinez-Nunez et al. 2011).
With the main goal of pro-inflammatory microglia being to protect the CNS against
invading pathogens, the upregulation of M1 receptors and cytokines assist with the defense
mechanisms. Communication with pro-inflammatory microglia and other immune cells is
possible through the presentation of the human leukocyte antigen-antigen D related (HLA-DR),
Fcϒ, and CD86 (Taylor et al. 2005). Additionally, the production of IL-12, ROS, and inducible
nitric oxide synthase (iNOS) assist with the M1 phenotype classification (Mantovani et al. 2004;
Kigerl et al. 2009).
Contrarily, the main purpose of the anti-inflammatory microglial mediators and receptors
is to promote repair, downregulate inflammation, and to encourage healthy CNS functions.
Some of the best characterized anti-inflammatory markers include the mannose receptor CD206,
a heparin-binding lectin Ym1, FIZZ1, and the enzyme arginase 1 (ARG 1), which has the ability
to decrease the production of iNOS (Stein et al. 1992; Corraliza et al. 1995; Hung et al. 2002;
Raes et al. 2002).
The anti-inflammatory phenotype is diverse; it can be broken down into subtypes. The
M2a subtype mainly focuses on suppressing inflammation and is induced by IL-4 and IL-13,
leading to the upregulation of ARG 1 (Stein et al. 1992). The exposure to IL-10, TGF-β, or
glucocorticoids allows for the M2c subtype, which appears to be involved in healing damaged
tissues after the pro-inflammatory phenotype is downregulated (Table 1) (Mantovani et al.
2004). The least understood subtype is the M2b classification, which slightly resembles the proinflammatory phenotype by lacking the anti-inflammatory markers previously discussed (Mosser
and Edwards 2008). The M2b microglia have a response most similar to the anti-inflammatory
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microglia in general, thus are listed as an M2 subtype. The lack of full understanding the M2
subtypes should yield caution to researchers attempting to study these subtypes separately, and
encourages viewing the M2 subtype as a spectrum within the anti-inflammatory phenotype
(Hanisch 2013).

Table 1. Characteristics of microglial phenotypes and subtypes
Phenotype/Subtype

Polarization

Cytokines
Released

Markers

Functions

Phagocytosis for
defense against
IL-1, IL-6, ILCD16, CD32,
IFNγ and LPSpathogens,
M1
12, IL-15, ILCD86, MHCII,
TLR4 signaling
release of NO,
23, and TNFα
and iNOS
and neuron
digestion
Inflammation
IGF 1, IL-10,
suppression,
CD163, CD204,
TGFβ, PDGF,
tissue repair, and
M2a
IL-4 or IL-13
CD206, ARG 1,
IL-1Ra, and
immune
Fizz1, and YM1
fibronectin 1
response against
parasites
ProCD86, CD163,
inflammatory
FcγR, IL1B, or
IL-1β, IL-6, ILMHCII, IL-10
M2b
and antiLPS-signaling
10, and TNFα
(high), IL-12
inflammatory
(low), SPHK1
functions
Healing
CD163, CD204,
functions and
M2c
IL-10 or TGFβ
Unknown
CD206, ARG 1
debris
scavenging
Adapted from “Repertoire of microglial and macrophage responses after spinal cord injury,” S.
David & A. Kroner, 2011, Nature Reviews. Neuroscience, 12(7), 388–99.

Following injury to the CNS, the pro-inflammatory response can be maintained during
the subacute and chronic phases, upholding a neurotoxic environment for the site of injury. The
anti-inflammatory response is limited to the subacute phase (Kigerl et al. 2009). In a study
performed by Kigerl et al., following a spinal cord injury, iNOS levels were increased drastically
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within the first three days of injury, a primary M1 response. During the monitored one-month
time period after the injury, M1 surface receptors CD86, CD16, and CD32 increased over time
(Kigerl et al. 2009). Anti-inflammatory microglia were upregulated initially, with IL-4 receptor
expression levels increasing more than twofold after 72 hours post injury, but M2 gene
expression returned to pre-injury levels by the seventh day. The decrease in the antiinflammatory phenotype suggests that chemokines and cytokines may cause existing microglia
to differentiate into the pro-inflammatory phenotype (Kigerl et al. 2009).

Microglia and ASD
Neuroinflammatory processes caused by chronically activated microglia can contribute to
the loss of synaptic connections and can cause neuronal death. The normal response to
inflammation is initiated by the pro-inflammatory microglial phenotype to encourage an immune
response against invaders and to engulf apoptotic neurons (Soehnlein and Lindbom 2010). The
response is then altered to an anti-inflammatory response, where angiogenesis is promoted and
cellular debris is cleared (Varin and Gordon 2009). When the pro-inflammatory response
continues rampantly, it can result in overproduction of inflammatory cytokines and ROS that
further induce tissue damage and cellular death (Kigerl et al. 2009).
Microglial dysfunction, shown in a mouse model of Rett syndrome, leads to neural
circuitry dysfunction and abnormal behavior. When microglial cells functioning abnormally, the
CNS becomes crowded with damaged cells, that impairs neural function (Derecki et al. 2012).
Additionally, when there is a lack of synaptic pruning, there is increased connectivity and
superfluous inputs between the synapses, also causing deficits in motor learning and associated
memory (Paolicelli et al. 2011). Neural function impairment and abnormal immune responses
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are distinct characteristics of ASD and have led scientists to hypothesize that there is a
connection between ASD and microglial responses.
During chronic neuroinflammation, the inflammatory reaction by microglia begins with
the typical pro-inflammatory response. The typical pro-inflammatory response is eventually
overtaken by the pro-inflammatory response, but during chronic neuroinflammation, the proinflammatory response becomes self-generating and does not cease. A destructive inflammatory
cycle is created, increasing inflammation and microglial activation further. The general shift
away from anti-inflammatory reparative processes has been hypothesized to be caused by a
failed anti-inflammatory microglial response (Amor et al. 2010; Rao et al. 2012). This failed
response might be due to decreased numbers of anti-inflammatory microglia or decreased
production of neuroprotective factors produced by the M2 phenotype.
Several studies have investigated the possibility that individuals with ASD suffer from
chronic neuroinflammation related to over-active microglia. One study in particular, performed
by Vargas and colleagues, examined the activation of microglia and astroglia in brains and
cerebral spinal fluid of autistic subjects. They found activation of astroglia and microglia, along
with active neuroinflammation in the white matter of the cerebral cortex and cerebellum. These
glial responses were proposed to be neuroinflammatory reactions of the CNS innate immune
system with microglial activation being the leading cellular response (Vargas et al. 2005).
In general, the majority of the studies that have studied microglial activation in various
other disorders have not specifically studied the different microglial phenotypes. While Vargas
et al. studied pro-inflammatory microglial cytokines and their putative role in chronic
neuroinflammation in ASD, this group did not study the anti-inflammatory microglial phenotype.
The paucity of data regarding the role of the different types of microglia in ASD drove the
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present investigation of both the pro-inflammatory and the anti-inflammatory microglial
phenotypes in ASD.

28

CHAPTER 2
METHODS
Brain Tissue
Flash-frozen postmortem BA24 tissue blocks from thirteen ASD donors and thirteen
typically developed control donors were acquired from Autism BrainNet (formerly Autism
Tissue Program, Harvard Brain Tissue Resource Center, Belmont, MA) and Neurobiobank
(formerly NICHD Brain and Tissue Bank for Developmental Disorders, Baltimore, MD). This
study was reviewed by the Institutional Review Board of East Tennessee State University, who
determined that it does not constitute human research under the Department of Health and
Human Services exemption 45 CFR 46.101(b) relating to the use of publicly available
unidentifiable pathology specimens. ASD and control donors were matched prior to
experimentation by gender, age, and RNA quality. Age and RNA quality were matched as
closely as possible with a difference of no more than three years in age and one RNA integrity
number for ASD and control donor pairs (Table 2).
ASD donors were diagnosed by the Autism Diagnostic Interview-Revised (ADI-R) and
met diagnostic criteria outlined in the Diagnostic and Statistical Manual (DSM) IV for autistic
disorder. For the protection of the identity of the ASD and control subjects, causes of death were
not incorporated in Table 2. Control donors died by drowning (3 donors), asphyxia (2 donors),
heart attack (2 donors), unspecified injuries (2 donors), dilated cardiomyopathy (1 donor), motor
vehicle accident (1 donor), pneumonia (1 donor), respiratory insufficiency (1 donor), asthma (1
donor), commotio cordis (1 donor), abdominal injuries (1 donor), and unknown cause (1 donor).
ASD donors died by asphyxia (2 donors), cardiac arrhythmia (2 donors), acute respiratory
distress syndrome (1 donor), bowel obstruction (1 donor), cancer (1 donor), congestive heart
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failure (1 donor), diabetic ketoacidosis (1 donor), motor vehicle accident (1 donor), stopped
breathing (1 donor), head trauma (1 donor), cardiopulmonary arrest (1 donor), skull fractures (1
donor), complications from seizure disorder (1 donor), and subdural hemorrhage (1 donor).

Table 2. Subject Demographic Information

Controls
Pair

IDa

Age

Gender

RINb

PMIc
(hours)

1
2
3
4
4*
5
6
7
8

AN14757
AN07176
AN07444
5408
4203
4848
5342
5079
M3231M

24
21
17
6
7
16
22
33
37

M
M
M
M
M
M
M
M
M

7.8
7.6
6.1
5.8
NA
7.5
8.0
5.3
4.9

21.33
29.91
30.75
16
24
15
14
16
24

9

AN12137

31

M

4.5

32.92

10
11
12
13
14

AN03217
AN00544
AN17425
4590
4670

19
17
16
20
4

M
M
M
M
M

5.3
5.8
6.8
6.8
6.2

18.58
28.92
26.16
19
17

17

4787

12

M

5.7

15

18

1105

16

M

7.8

17

MEAN
SEM

18.71
2.21

6.37
0.27

21.50
1.52
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Toxicology

Sertraline

Ethanol

Singular,
Albuterol,
Prednisone,
Claritin

Tissue
Preservation

Matter
Type used
for qPCRd

Frozen
Frozen
Frozen
Frozen
Fixed
Frozen
Fixed, Frozen
Frozen
Frozen
Frozen

WMe
WM, GMf
WM
WM
NA
WM, GM
WM, GM
WM, GM
WM, GM

Frozen
Frozen
Frozen
Fixed, Frozen
Frozen

WM, GM
WM, GM
WM, GM
WM, GM
WM, GM

Frozen

GM

Frozen

GM

WM, GM

Table 2 (continued)

ASD
Tissue
Preservation

Matter
Type used
for qPCR

18.51

Frozen

WM

7.0
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Frozen

WM, GM

6.7
8.0

30.83
3

Frozen
Fixed, Frozen

WM
WM

Frozen

WM, GM

Fixed, Frozen

WM, GM

Frozen

WM, GM

Frozen

WM, GM

Frozen
Frozen
Frozen
Frozen
Fixed, Frozen
Frozen
Frozen
Frozen

WM, GM
WM, GM
WM, GM
WM, GM
WM, GM
WM, GM
GM
GM

Pair

ID

Age

Gender

RIN

PMI
(hours)

1

AN04166

24

M

8.1

2

AN03935

19

M

3
4

AN02987
5144

15
7

M
M

5

5302

16

M

4.8

20

6

5176

22

M

5.1

18

7

5297

33

M

2.5

50

8

5027

37

M

4.7

26

9
10
11
12
13
14
17
18

AN11989
AN07817
AN00764
AN04682
4999
5308
5565
5403

30
19
20
15
20
4
12
16

M
M
M
M
M
M
M
M

5.7
4.5
5.9
5.6
7.0
7.0
7.0
6.6

16.06
14.83
23.66
23.23
14
21
22
35

MEAN
SEM
P-valueg

19.31
2.18
0.85

6.01
0.36
0.45

22.76
2.60
0.67

Toxicology

Risperdal,
Luvox,
Clonidine,
Insulin
Risperdal
Seroquel,
Prozac,
Depakote,
Geodon
Risperdal,
Luvox

Minocycline

4* used as a control match for ASD (ID 5144) for fixed tissue stain only
IDa= identification number
RINb= RNA integrity number
PMIc= post-mortem interval
qPCRd= quantitative real-time polymerase chain reaction
WMe= white matter
GMf= gray matter
P-valueg= results of an independent t-test comparing control and ASD groups, statistically significant when p<0.05
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Tissue Preparation and Sectioning
Frozen BA24 tissue was sectioned at thicknesses of 50 µm and 10 µm at -20°C using a
cryostat microtome (Leica CM3050S) for differential gene expression analysis and
immunohistochemical identification respectively. Tissue sections were mounted on room
temperature (22°C) slides and were desiccated at room temperature for 5 minutes before being
stored at -80°C. To avoid cross contamination between subjects, the internal elements of the
microtome were cleaned using 100% ethanol. Tissue sections from subject pairs were prepared
on the same day to guarantee equal storage time.

Laser Capture Microdissection and Punch-Dissection
Areas 4.5 mm2 of white matter from 20 µm-thick frozen tissue sections were captured by
laser capture microdissection (LCM) using an Arcturus XT (Life Technologies, Grand Island,
NY) instrument. An ultraviolet laser cut the white matter sections from the surrounding tissue
and these were then placed onto CapSure macrocaps by infrared laser spotting. Additionally,
white and gray matter, containing superficial and deep matter, from 50 µm tissue sections were
grossly punch-dissected, using a disposable 3.5 mm trephine. The LCM white matter was
removed from the cap using lysis buffer incubation at 42°C. Dissected tissues were stored at 80°C and were later homogenized for RNA isolation.

RNA and cDNA Preparation
Total RNA was isolated from the LCM white matter and some of the white matter
punches (used to study the expression of CD68 and IL1B) using a Maxwell 16 LEV simplyRNA
Tissue Kit (Promega, Madison, WI). A Direct-zol RNA MicroPrep Kit (Zymo Research, Irvine,
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CA) was used extract total RNA from the gray matter and remaining white matter punches for
the analysis of the expression of the remaining genes. RNA quality was assessed by measuring
RIN values with the Bioanalyzer RNA 6000 Nano chip (Agilent Technologies, Santa Carla, CA)
and the Agilent 2200 TapeStation (Agilent Technologies, Santa Clara, CA) respectively. Double
stranded cDNA was made by reverse transcription of the RNA samples using the Superscript III
kit (Life Technologies; Grand Island, NY) that utilized both oligodTs and random hexamer
primers during synthesis.

Polymerase Chain Reactions
Five primers were purchased (Qiagen; Valencia, CA) while the remaining seven primers
were designed using PrimerQuest software (Integrated DNA Technologies, Coralville, IA) Table
3. The gene sequences for the designed primers are listed in Appendix B. For primer
temperature and cycle number optimization, end-point polymerase chain reaction (PCR) was
performed using a T100 Thermo Cycler (Bio-Rad, Hercules, CA). Each reaction contained
SYBR Green Master Mix (Qiagen; Valencia, CA), cDNA template, and gene specific primers.
Gene expression results from LCM white matter and white matter punches were
compared by quantitative real-time polymerase chain reaction (qPCR) to determine which tissue
isolation technique ultimately yielded sufficient amounts of RNA for the gene expression
studies. Once determined, qPCR was performed for all gene expression analyses. Each PCR
reaction was performed in triplicate and a standard curve was used to determine the efficiency of
reactions. Medians of triplicates were used for statistical analysis to reduce the impact of
outliers.

33

Table 3. Introduction to the reference genes, pro-inflammatory microglial markers, and antiinflammatory microglial markers used for gene expression and immunohistochemistry
Protein
Brief Description of Function
Name
Reference Genes

Gene
Name

Alias

GAPDH

Glyceraldehyde-3-phosphate
dehydrogenase

GAPDH

Catalyzes an energy-yielding step in glycolysis

TATA
(TBP)

TATA-box binding protein

TBP

Transcription factor

Pro-inflammatory Microglial Markers
CD68

Cluster of differentiation 68

CD68

Cell surface protein that clears cellular debris, and
promotes phagocytosis

HLA-DRA

Major histocompatibility
complex, class II, DR alpha
chain

HLA-DRA

Presents peptide antigens that are able to create an
immune response

IL1B

Interleukin 1 beta

IL1β

NOS2

Nitric oxide synthase 2

iNOS

PTGS2

Prostaglandin-endoperoxide
synthase 2 (inducible)/
cyclooxygenase

COX2

Cytokine mediator in inflammatory responses and
involved in cell proliferation, differentiation, and
apoptosis
Enzyme that generates nitric oxide (reactive free
radical)
Enzyme responsible for prostanoid biosynthesis
involved in inflammation and mitogenesis

Anti-inflammatory Microglial Markers
ARG1

Arginase 1

ARG1

IGF1

Insulin like growth factor 1

IGF1

MRC1

Mannose receptor, C type 1

CD206

PPARG

Peroxisome proliferative
activated receptor gamma

PPARγ

Enzyme that converts arginine into compounds used
for wound repair and down-regulates nitric oxide
Ligand that stimulates proliferation of
oligodendrocytes (supports myelination of neuronal
axons)
Receptor that binds and internalizes mannosylated
ligands on potentially pathogenic microorganisms so
they can be neutralized by phagocytic engulfment
Receptor that inhibits pro-inflammatory gene
expression

Statistical Analysis
Expression data for target genes was normalized to reference genes GAPDH and TATA.
Fold changes in the expression of genes of interest comparing ASD to control subjects were
obtained using the 2-∆∆Ct method of Livak and Schmittgen (Livak and Schmittgen 2001). For
these calculations, the geometric means of Ct values of reference genes were used for
normalizations. SPSS (version 22, IBM, New York, NY) was used to identify and remove
extreme outliers in data sets based on the outlier labeling rule that utilizes the third and first
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quartiles and a multiplying factor of 2.2 (Hoaglin and Iglewicz 1987). Normality tests were run
using GraphPad Prism (version 5.0b, GraphPad Software, Inc.) and regressions were performed
using SPSS. GraphPad Prism was used to analyze the data using an independent student’s t-test.
Data that was not normally distributed were analyzed using the Mann-Whitney non-parametric
test. Results were considered statistically significant when p-value< 0.05. Statistical results are
reported before and after Holm’s Bonferroni correction for the number of gene comparisons.

Immunohistochemistry
Pro-inflammatory
For visualization of pro-inflammatory microglial cells, frozen tissue sections, n=8 pairs,
were immunohistochemically stained for the HLA-DRA pro-inflammatory microglial protein.
The slides that were used for analysis were removed from the -80°C freezer and were
immediately transferred into -20°C acetone (13 min). Endogenous peroxidase activity in the
tissue was neutralized in 0.1M PBS/ 1.5% H2O2 (15 min). After the tissue was blocked with 3%
BSA (1 h), the sections were incubated with a monoclonal mouse anti-human HLA-DR antigen,
alpha-chain clone TAL.1B5 (Dako, Carpinteria, CA) at a dilution of 1:100 (overnight at 4°C).
Following primary antibody incubation, the sections were incubated in a corresponding
secondary antibody, Vectastain mouse IgG ABC kit (Vector Laboratories Inc, Burlingame, CA)
(2 h), and then with avidin-biotinylated horseradish peroxidase complex (1 h). Sections were
washed in 0.1M PBS (10 min), then 0.05 M Tris (2 times for 10 min each). The proinflammatory microglial cells were then visualized by incubating sections in 50 mL of 0.05M
Tris, 0.3% ammonium nickel sulfate, and 3,3’-diaminobenzidine tetrahydrochloride (5 min), then
in another 50 mL of the same solution, but also containing 50 µl H2O2 (5 min). Between all
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remaining incubation steps, excluding between blocking and primary antibody incubation,
sections were washed in 0.1M PBS (3 times for 10 min each). Sections were dehydrated in
sequential washes of 75%, 95%, and 100% ethanol (30 sec each). The final dehydration step
was in xylene (5 min) and the sections were then dried in the hood (5 min) in preparation for
analysis. The attempted protocols during the optimization process can be found in sequential
order in Table 4.

Table 4. Attempted protocols for the HLA-DRA immunohistochemical stain on frozen and fixed tissue
Buffer

Block

0.05M TBS

NHSa/ 0.05M
TBS + 0.2%
Triton-X-100 +
2% SA
NHS/ 0.05M
TBS + 0.2%
Triton-X-100 +
2% SA
3% BSA/ 0.1M
PBS

*0.05M TBS

0.1M PBS

Primary
Antibody
Manufacturer
and Dilution
Dakob
1:100

Dako
1:100

Dako
1:100

Components
for Primary
Antibody
Incubation
NHS/ 0.05M
TBS + 0.2%
Triton-X-100 +
2% SA
NHS/ 0.05M
TBS + 0.2%
Triton-X-100 +
2% SA
NHS/ 0.1M
PBS

Secondary
Antibody
Manufacturer
and Dilution
Vectorc
1:200

Vector
1:200

Components for
Secondary
Antibody
Incubation
Horse Serumd/
0.05M TBS +
0.2% Triton-X100
Horse Serum/
0.05M TBS +
0.2% Triton-X100
Horse Serum/
0.1M PBS

Vector
1:200

Developer
DABe

DAB

DAB

0.1M PBS

3% BSA/ 0.1M
PBS

Dako
1:100 and
1:200

NHS/ 0.1M
PBS

Vector
1:200

Horse Serum/
0.1M PBS

DAB

0.05M PBS

3% BSA/
0.05M PBS

Dako
1:100

NHS/ 0.05M
PBS

Vector
1:200

Horse Serum/
0.05M PBS

DAB

0.1M PBS

3% BSA/ 0.1M
PBS

Dako
1:100

NHS/ 0.1M
PBS

Vector
1:400

Horse Serum/
0.1M PBS

DAB

**0.1M PBS

3% BSA/ 0.1M
PBS + 0.2%
Tween 20
6% BSA/ 0.1M
PBS + 0.2%
Tween 20

Dako
1:100

NHS/ 0.1M
PBS + 0.2%
Tween 20
NHS/ 0.1M
PBS + 0.2%
Tween 20

Vector
1:400

Horse Serum/
0.1M PBS +
0.2% Tween 20
***
Horse Serum/
0.1M PBS +
0.2% Tween 20

DAB

**0.1M PBS

Dako
1:100
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Vector
1:400

DAB

Table 4 (continued)
**0.1M PBS

3% BSA/ 0.1M
PBS + 0.2%
Tween 20;
NHS/ 0.1M
PBS + 0.2%
Tween 20
NHS/ 0.1M
PBS + 0.1%
Tween 20;
NHS/ 0.1M
PBS + 0.2%
Triton-X-100
NHS/ 0.1M
PBS + 0.2%
Triton-X-100

Dako
1:100

NHS/ 0.1M
PBS + 0.2%
Tween 20

Vector
1:400

Horse Serum/
0.1M PBS +
0.2% Tween 20

DAB

Dako
1:100

NHS/ 0.1M
PBS + 0.1%
Tween 20;
NHS/ 0.1M
PBS + 0.2%
Triton-X-100
NHS/ 0.1M
PBS + 0.2%
Triton-X-100

Vector
1:400

Horse Serum/
0.1M PBS +
0.1% Tween 20;
NHS/ 0.1M PBS
+ 0.2% TritonX-100
***Horse
Serum/ 0.1M
PBS + 0.2%
Triton-X-100

DAB

3% BSA/ 0.1M
PBS + 0.2%
Triton-X-100;
3% BSA/NHS/
0.1M PBS +
0.2% Triton-X100
6% BSA/ 0.1M
PBS + 0.2%
Triton-X-100

NoneNegative
Optimization

NHS/ 0.1M
PBS + 0.2%
Triton-X-100

Vector
1:400

Horse Serum/
0.1M PBS +
0.2% Triton-X100

DAB

NoneNegative
Optimization

NHS/ 0.1M
PBS + 0.2%
Triton-X-100

Vector
1:400

DAB

**0.1M PBS

3% BSA/ 0.1M
PBS + 0.2%
Triton-X-100

NoneNegative
Optimization

NHS/ 0.1M
PBS + 0.2%
Triton-X-100;
NHS/ 0.1M
PBS

Vector
1:400

**0.1M PBS

1% BSA/ 0.1M
PBS + 0.2%
Triton-X-100

Dako
1:100

1% BSA/ 0.1M
PBS + 2%
Triton-X-100

Jackson
AffiniPureg
1:400

Horse Serum/
0.1M PBS +
0.2% Triton-X100
Horse Serum/
0.1M PBS +
0.2% Triton-X100; Horse
Serum/ 0.1M
PBS
1% BSA/ 0.1M
PBS + 2%
Triton-X-100

**0.1M PBS

1% BSA/ 0.1M
PBS

Dako
1:100

1% BSA/ 0.1M
PBS

Jackson
AffiniPure
1:400

1% BSA/ 0.1M
PBS

NovaRed

**Wash
Bufferh

Blocking
Bufferh

Dako
1:100

Blocking
Buffer

Blocking Buffer

DAB/Metal
Concentrateh

0.1M PBS

0.1M PBS +
0.2% Triton-X100

Dako
1:100

NHS/ 0.1M
PBS + 0.2%
Triton-X-100

Life
Technologiesi
1:3000
Vector
1:200

Horse Serum/
0.1M PBS +
0.2% Triton-X100

None-Fixed
Tissue

* **0.1M
PBS

**0.1M PBS

**0.1M PBS

**0.1M PBS

Dako
1:100

Vector
1:400

*Stain incubated at 37°C instead of 25°C
**Stain performed by Emma E. Pendola under my supervision
***incubated for 2 separate amounts of time
NHSa= Normal Horse Serum
Dakob=Monoclonal Mouse Anti-Human HLA-DR Antigen, Alpha-Chain Clone TAL.1B5
Vectorc=Mouse IgG ABC kit used for bright-field microscopy
Horse Serumd= component of the Vector Mouse IgG ABC kit
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DAB

NovaREDf

NovaRED

DABe= 3,3’-diaminobenzidine tetrahydrochloride
NovaREDf=Vector NovaRED Peroxidase (HRP) Substrate Kit
Jackson AffiniPureg= Peroxidase-conjugated AffiniPure Donkey Anti-Mouse IgG used for bright-field microscopy
Wash Buffer, Blocking Buffer, and DAB/Metal Concentrateh= components of the Thermo Pierce Peroxidase Detection Reagent
Pack
Life Technologiesi= HRP-Goat Anti-Mouse IgG

Anti-inflammatory
As an attempt to visualize the anti-inflammatory microglial cells, the mannose receptor,
CD206, was chosen as the cellular marker. For bright-field and fluorescent microscopy, a Pierce
mannose receptor/CD206 antibody (Thermo Fisher, Rockford, IL) and purified mouse antihuman CD206 antibody (BD Pharmigen, San Jose, CA) were used for primary antibody
incubations. The secondary antibodies used for bright-field microscopy included: a secondary
antibody from a Vectastain mouse IgG ABC kit (Vector Laboratories Inc, Burlingame, CA), an
ECL anti-mouse IgG horseradish peroxidase linked whole antibody (GE Healthcare UK Limited,
Buckinghamshire, UK) and a peroxidase-conjugated AffiniPure donkey anti-mouse IgG (Jackson
Immuno, West Grove, PA). An Alexa Fluor 488-conjugated AffiniPure donkey anti-mouse IgG
(Jackson Immuno, West Grove, PA) was used as the secondary antibody for fluorescent
microscopy. For bright-field microscopy, all slides were immediately transferred from the -80°C
freezer into cold acetone (stored at -20°C) for fixation of the tissue to the slide (rapid stain (r): 5
min; overnight stain (o): 10 min). For fluorescent microscopy, all slides were transferred from
the -80°C freezer to a desiccator (5-10 min) prior to fixation by acetone. Endogenous peroxidase
activity in the tissue was neutralized in 0.1M PBS/H2O2 (bright-field only). After the tissue was
blocked (r: 10 min; o: 2 h), the sections were incubated in primary antibody at various dilutions.
Following primary antibody incubation (r: 15 min; o: overnight), the sections were incubated in a
corresponding secondary antibody (r: 10 min; o: 2 h) and then with avidin-biotinylated
horseradish peroxidase complex (r:10 min; o:1 h), excluding the protocols when the Thermo
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Pierce Peroxidase Detection Reagent Pack was used. When the Thermo Pierce Pack was not
used, sections were washed in the corresponding buffer and were visualized by incubating
sections in 50 mL of 0.05M Tris, 0.3% ammonium nickel sulfate, and 3,3’-diaminobenzidine
tetrahydrochloride (r and o: 5 min), then in another 50 mL of the same solution, but also
containing 50 µl H2O2 (r: 5 min; o: 10 min). The Thermo Pierce Pack did not require the
previous step, but instead, the sections were incubated in the Thermo Pierce DAB/Metal
Concentrate (r: 5 min). Between all remaining incubation steps, excluding between blocking and
primary antibody incubation, sections were washed in the corresponding buffer. All sections for
bright-field microscopy were dehydrated before analysis sequentially in 75%, 95%, and 100%
ethanol (30 sec each) and xylene (5 min), while the sections for fluorescent microscopy were
prepared for analysis using a Slowfade Antifade Kit (Invitrogen, Rockford, IL). The components
for the intermediate steps of each attempted protocol are listed in Table 5.

Table 5. Attempted protocols for the CD206 immunohistochemical stain on frozen tissue
Buffer

Block

Primary
Antibody
Manufacturer
and Dilution

0.1M
PBS

3% BSA/
0.1M PBS

Thermo Fishera
1:500

NHS/ 0.1M PBS

Vector
1:200

Horse Serum/ 0.1M
PBS

DAB

0.1M
PBS

3% BSA/
0.1M PBS

Thermo Fisher
1:250

NHS/ 0.1M PBS

Vector
1:200

Horse Serum/ 0.1M
PBS

DAB

0.05M
TBS

3% BSA/
0.1M PBS

Thermo Fisher
1:500

NHS/ 0.1M PBS

Vector
1:200

Horse Serum/ 0.1M
PBS

DAB

Thermo Fisher
1:500

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

Thermo Fisher
1:250

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

0.1M
PBS

0.1M
PBS

3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100

Components
for Primary
Antibody
Incubation

Secondary Antibody
Manufacturer and
Dilution

Components for
Secondary
Antibody
Incubation

Developer
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Table 5 (continued)

0.1M
PBS

0.1M
PBS

0.1M
PBS

0.1M
PBS

0.1M
PBS

0.1M
PBS

0.1M
PBS

0.1M
PBS

0.1M
PBS

3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100

None-Negative
Optimization

1% BSA/ 0.1M
PBS + 0.2%
Triton-X-100

Vector
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

None-Negative
Optimization

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

Thermo Fisher
1:125

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

None-Negative
Optimization

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Jackson AffiniPureb
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

Thermo Fisher
1:125

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Jackson AffiniPure
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

Thermo Fisher
1:250

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

Thermo Fisher
1:125

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:400

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

Thermo Fisher
1:125

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:400

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

Thermo Fisher
1:125

1% BSA/ 0.1M
PBS + 0.2%
Triton-X-100

Jackson
1:200

1% BSA/ 0.1M PBS
+ 0.2% Triton-X100

Nova RED

0.1M
PBS

3% BSA/
0.1M PBS

Thermo Fisher
1:125

1% BSA/ 0.1M
PBS

Vector
1:400

1% BSA/ 0.1M PBS

DAB

0.1M
PBS

3% BSA/
0.1M PBS

Thermo Fisher
1:125

1% BSA/ 0.1M
PBS

Jackson AffiniPure
1:200

1% BSA/ 0.1M PBS

Nova RED

0.1M
PBS

3% BSA/
0.1M PBS

Pharmigenc
1:500

NHS/ 0.1M PBS

Vector
1:200

Horse Serum/ 0.1M
PBS

DAB

Pharmigen
1:250

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

None-Negative
Optimization

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

0.1M
PBS

0.1M
PBS

3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
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Table 5 (continued)

0.1M
PBS

0.1M
PBS

0.1M
PBS

0.1M
PBS

0.1M
PBS

3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100
3% BSA/
0.1M PBS +
0.2% TritonX-100

Thermo Fisher
1:250

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

Pharmigen
1:125

1% BSA/ 0.1M
PBS + 0.2%
Triton-X-100

Vector
1:400

1% BSA/ 0.1M PBS
+ 0.2% Triton-X100

DAB

Pharmigen
1:250

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:200

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

Pharmigen
1:125

NHS/ 0.1M PBS
+ 0.2% TritonX-100

Vector
1:400

Horse Serum/ 0.1M
PBS + 0.2% TritonX-100

DAB

Pharmigen
1:125

1% BSA/ 0.1M
PBS + 0.2%
Triton-X-100

Jackson AffiniPure
1:200

1% BSA/ 0.1M PBS
+ 0.2% Triton-X100

NOVA Red

Blocking Buffer

DAB/Metal
Concentrate

Blocking Buffer

DAB/Metal
Concentrate

GE Healthcare UK
Limitedd
1:200
GE Healthcare UK
Limited
1:500 and 1:1000

Wash
Buffer

Blocking
Buffer

None-Negative
Optimization

Blocking Buffer

Wash
Buffer

Blocking
Buffer

None-Negative
Optimization

Blocking Buffer

Wash
Buffer

Blocking
Buffer

None-Negative
Optimization

Blocking Buffer

Thermo Fisher
1:1000

Blocking Buffer

DAB/Metal
Concentrate

Wash
Buffer

Blocking
Buffer

None-Negative
Optimization

Blocking Buffer

None-Negative
Optimization

Blocking Buffer

DAB/Metal
Concentrate

0.1M
PBS

3% BSA/
0.1M PBS

None-Negative
Optimization

NHS/ 0.1M PBS

None-Negative
Optimization

Horse Serum/ 0.1M
PBS

DAB

Wash
Buffer

Blocking
Buffer

None-Negative
Optimization

Blocking Buffer

None-Negative
Optimization

Blocking Buffer

DAB/Metal
Concentrate

0.1M
PBS

10% Donkey
Serum/ 3%
BSA/ 0.1M
PBS

Thermo Fisher
1:125

1% BSA/ 0.1M
PBS

Jackson Immunoe
1:500

1% BSA/ 0.1M PBS

NA

0.1M
PBS

10% Donkey
Serum/ 0.1M
PBS + 0.1%
Tween 20

Pharmigen
1:75 and 1:250

0.1M PBS +
0.1% Tween 20

Jackson Immuno
1:500

0.1M PBS + 0.1%
Tween 20

NA

Thermo Fishera= Pierce Mannose Receptor/CD206 used for bright-field microscopy
Jackson AffiniPuref= Peroxidase-conjugated AffiniPure Donkey Anti-Mouse IgG used for bright-field microscopy
Pharmigeng=Purified Mouse Anti-Human CD206 used for bright-field microscopy
GE Healthcare UK Limitedi=ECL Anti-Mouse IgG, Horseradish Peroxidase linked wholeantibody used for bright-field
microscopy
Jackson Immunoj= Alexa Fluor 488-conjugated AffiniPure Donkey Anti-Mouse IgG used for fluorescence microscopy
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Immunohistochemical Analysis
ImageJ software (version 1.44o) was used to calculate the area fraction of HLA-DRA
labeled microglial cells. To calculate the amount of HLA-DRA immunoreactivity in a specific
area, images of HLA-DRA labeled tissue from control and ASD subjects were converted into an
8-bit image. Ten randomized images were taken for each tissue section and a fixed threshold
was determined by taking the average threshold from all slides. Fractional area was calculated
by dividing the HLA-DRA positive area (µm2) in the 8-bit image by the total area of the image
frame. The data were analyzed using an independent and dependent student’s t-test for ASD and
age-matched control donors. Results were considered statistically significant when p<0.05.
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CHAPTER 3
RESULTS
Subject Demographics
Control and ASD donors were matched by gender, age, and RIN. Donors were matched
within 3 years of age and 1 RIN value (Auer et al. 2003). While PMI was not a factor in
matching donor pairs, it was analyzed and compared statistically to ensure there was no
difference between ASD and matched control donors. There was no significant difference in the
average age (p= 0.920; Figure 1), RIN values (p= 0.446; Figure 2), nor PMI (p= 0.649; Figure
3) when comparing ASD to matched control donors.

Figure 1. Comparison of average age of ASD and matched control donors (n=18 pairs). No
statistically significant difference was observed.
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Figure 2. Comparison of average RIN value of ASD and matched control donors (n=18 pairs).
No statistically significant difference was observed.

Figure 3. Comparison of average PMI of ASD and matched control donors (n=18 pairs). No
statistically significant difference was observed.
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Gene Expression
White Matter
In initial work, it was determined that gross punch-dissection of human BA24 white
matter yielded sufficient amounts of RNA for gene expression studies so that the laser capture
microdissection of white matter would not be required. Following the conclusion that punches
could be used, expression levels of both pro-inflammatory and anti-inflammatory microglial
target genes were measured in punch-dissected white matter from ASD and control donors.
Target gene expression data was normalized to two reference genes, GAPDH and TATA, after it
was determined that there was no significant difference in the GAPDH/TATA ratio comparing the
typically developed control donors and ASD donors (p= 0.088; Figure 4A), (p= 0.263; Figure
4B).

Figure 4. Ratio of housekeeping genes GAPDH/TATA used for the normalization of the gene
expression data for CD68, IL1B (A, n=11 pairs), ARG1, HLA-DRA, IGF1, MRC1, NOS2,
PPARG, and PTGS2 (B, n= 10 pairs) in white matter of typically developed control and ASD
donors. No statistically significant differences were observed when the two groups of donors
were compared.

The expression of five pro-inflammatory microglial genes were measured by qPCR in
post-mortem BA24 tissue that was punch-dissected from the white matter of individuals with
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ASD and matched controls. Figure 5 displays expression levels of the five pro-inflammatory
microglial genes in white matter tissues. There were no statistically significant differences in the
expression levels of CD68 (p= 0.493), HLA-DRA (p= 0.995), IL1B (p= 0.149), NOS2 (p= 1.000),
nor PTGS2 (p= 0.657) comparing ASD and control groups.
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Figure 5. Expression of pro-inflammatory microglial genes HLA-DRA (A), NOS2 (B), PTGS2
(C), CD68 (D), and IL1B (E) in white matter from matched pairs of ASD (closed symbols) and
control (open symbols) donors (A, B, and C, n=10 pairs; D and E, n=11 pairs). Gene expression
levels were normalized to the geometric mean of stable reference genes (GAPDH and TATA).
Mean values are indicated by horizontal lines. No statistically significant differences were
observed when the two groups of donors were compared.

47

Likewise, analyses of the expression levels of four anti-inflammatory microglial
expressed genes also demonstrated no statistically significant differences when comparing the
two groups of donors (Figure 6); ARG1 (p= 0.500), MRC1 (p= 0.553), and PPARG (p= 0.336).
In contrast, IGF1 expression levels were significantly higher in ASD donors as compared to
control donors (p= 0.014).

Figure 6. Expression of target anti-inflammatory microglial genes ARG1 (A), IGF1 (B), MRC1
(C), and PPARG (D) in white matter from matched pairs of typically developed control (open
symbols) and ASD (closed symbols) donors (n=10 pairs). Gene expression levels were
normalized to the geometric mean of stable reference genes (GAPDH and TATA). Mean values
are indicated by horizontal lines and statistical significance is indicated above the data points.
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Gray Matter
Target gene expression data was normalized to two reference genes, GAPDH and TATA,
after it was determined that there was no significant difference in the GAPDH/TATA ratio when
comparing typically developed control donors and ASD donors (p= 0.558; Figure 7).

Figure 7. Ratio of housekeeping genes GAPDH/TATA used for the normalization of the gene
expression data for HLA-DRA, IGF1, IL1B, and MRC1 in the gray matter of typically developed
control and ASD donors (n=13 pairs). No statistically significant difference was observed when
the two groups of donors were compared.

Chosen for examination in gray matter was IGF1 because its expression demonstrated
differences between the two study groups in white matter. In addition, pro-inflammatory, HLADRA, and anti-inflammatory microglial genes, MRC1, were selected to parallel the markers used
in the immunohistochemistry portion of the study. Although there was no significant difference
in IL1B expression levels in white matter comparing the two groups of donors, the expression of
IL1B exhibited a wide range of Ct values in the ASD donors (Figure 5E) and was chosen as
well.
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The expression levels of MRC1 in gray matter were significantly lower in ASD donors as
compared to typically developed control donors (p= 0.034; Figure 8A). In contrast to the white
matter results, there was no significant difference in the expression of anti-inflammatory IGF1 in
gray matter (p= 0.273; Figure 8B). The expression of HLA-DRA was similar when comparing
ASD to matched control donors (p= 0.301; Figure 9).
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Figure 8. Expression of anti-inflammatory MRC1 (A, n= 12 control and 13 ASD donors) and
IGF1 (B, n=13 pairs) in gray matter in typically developed control (open symbols) and ASD
(closed symbols) donors. Gene expression levels were normalized to the geometric mean of
stable reference genes (GAPDH and TATA). Mean values are indicated by horizontal lines and
statistical significance is indicated above the data points.
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Figure 9. Expression of pro-inflammatory HLA-DRA in gray matter in typically developed
control (open symbols) and matched ASD (closed symbols) donors (n=13 control and 12 ASD
donors). Gene expression levels were normalized to the geometric mean of stable reference
genes (GAPDH and TATA). Mean values are indicated by horizontal lines. No statistically
significant difference was observed when the two groups of donors were compared.

The expression levels of IL1B demonstrated wide variation in comparison to the other
gene expressions that were studied, just as occurred in IL1B expression levels in white matter
(Figure 5E). While there was no significant difference in the expression of IL1B when
comparing ASD to matched control donors, this wide variation of IL1B expression fold changes
comparing the two groups is interesting. We provide a combination of two figures for IL1B
expression in gray matter (Figure 10); the circular and diamond symbols combined depicts the
range of data before outliers were removed by the outlier labeling rule (with the statistical
comparison generating a p= 0.719), while the circular symbols alone illustrate the data after 3
outliers were removed (generating a p= 0.951). One outlier was removed from the control data
(open diamond symbol), while two outliers were removed from the ASD data set (closed
diamond symbols). Hence, removing outliers in the IL1B dataset, as was performed for all data
sets, resulted in hiding the fact that IL1B expression levels were highly variable in ASD subjects.
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Figure 10. Expression of anti-inflammatory IL1B in gray matter pre-removal of outliers with the
outlier labeling rule (diamond symbols and dotted horizontal lines) (n=13 pairs) and postremoval of the outliers (circular symbols and solid horizontal lines) (n=12 control and 11 ASD
donors) in typically developed control (open symbols) and ASD (closed symbols) donors. Gene
expression levels were normalized to the geometric mean of stable reference genes (GAPDH and
TATA). Mean values are indicated by horizontal lines. No statistically significant differences
were observed when the two groups of donors were compared, whether outliers are removed or
not.

Statistical Limitations of the Study
Due to the number of statistical comparisons of gene expression levels, it was necessary
to report corrected p-values to reduce the chance of a type I error. Hence, the Holm’s Bonferroni
correction was used to adjust p-values (Table 6). After the correction, the group comparison of
IGF1 expression levels in white matter was no longer statistically significant (p’=0.112).
Likewise, the comparison of MRC1 expression levels in gray matter in the two groups also failed
to reach statistical significance (p’=0.136).
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Table 6. P-values after Holm's Bonferroni correction for multiple independent student’s t-tests of
gene expression from ACC white and gray matter in ASD and control donors
WHITE MATTER
Gene

p-value p’ (Adjusted p-value)

Outcome

IGF1
IL1B
PPARG
CD68
ARG1
MRC1

0.014
0.149
0.336
0.493
0.500
0.553

0.112
1.000
1.000
1.000
1.000
1.000

Not significant
Not significant
Not significant
Not significant
Not significant
Not significant

PTGS2

0.657

1.000

Not significant

HLA-DRA

0.995

1.000

Not significant

NOS2

1.000

1.000

Not significant

GRAY MATTER
Gene

p-value p’ (Adjusted p-value)

Outcome

MRC1

0.034

0.136

Not significant

IGF1

0.273

0.819

Not significant

HLA-DRA

0.301

0.819

Not significant

IL1B with outliers

0.719

0.819

Not significant

IL1B outliers removed

0.951

0.951

Not significant

Calculations adapted from “A simple sequential rejective method procedure,” S. Holm, 1979,
Scandinavian Journal of Statistics, 6, 65-70.

Immunohistochemistry
HLA-DRA
Frozen BA24 tissue (20 µm thick) sections were stained using an antibody directed
against HLA-DRA. Area fraction (area of positive staining as a fraction of the entire area
analyzed) averages were calculated from ten randomly selected white matter areas per subject
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(Figure 11). No statistically significant difference was found when comparing control and ASD
donors (p= 0.250; Figure 12; n=8 pairs).

CONTROL (20x)

ASD (20x)

Figure 11. Immunohistochemical stain for the pro-inflammatory microglial marker HLA-DRA
in a representative typically developed control donor and paired ASD donor.
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Figure 12. Comparison of area fractions of immunohistochemically stained HLA-DRA in
control and ASD donor postmortem tissue (n= 8 pairs). No statistically significant difference
was observed when the two donor groups were compared.

CD206
For each procedure, excluding the protocols for negative optimization, there was a
positive stained and background slide. The positive stained slide was incubated in both primary
and secondary antibody, while the background slide was incubated in buffer with only the
secondary antibody (minus the primary antibody). The purpose of having both conditions was to
verify that what is being stained is not artifactual. During the process of optimization, it
appeared that there might be some type of artifact as a result of freezing the tissue. Despite
testing multiple primary and secondary antibodies for the mannose receptor, CD206, in the
immunohistochemistry experiments, there was no successful identification of this antiinflammatory microglial protein marker in white matter.
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CHAPTER 4
DISCUSSION
ASD is considered a spectrum disorder of atypical connections between brain areas,
causing deficits in speech, motor skills, and social interaction. Most research to date has focused
on the role of neurons in ASD pathology, while other major cell types in the brain have received
far less attention. In the past, our lab has investigated the role of neurons and macroglia
(astrocytes and oligodendrocytes) in ASD pathology, but not microglia. As the immune cells for
the CNS, microglia protect the brain from pathogenic factors and preserve homeostatic
conditions via synaptic pruning and phagocytosis of apoptotic neurons. Microglia are
differentiated into two distinct phenotypes: pro-inflammatory and anti-inflammatory. Proinflammatory microglia produce cytokines and assume phagocytic roles that promote defense
mechanisms and digest neurons. In contrast, anti-inflammatory microglia facilitate CNS healing
by participating in phagocytosis, neuronal remodeling, and tissue regeneration. Given these
extremely important roles of microglia in the CNS, it is imperative to characterize and determine
the potential contributory role of these cells to the pathology of ASD.
Within the field of ASD research, pathology studies using postmortem brain tissues have
been mainly limited to examining brain areas as a whole, without considering potential
differences in white and gray matter. It is known that microglia reside in both white and gray
matter, however; it is still unknown whether there is a difference in the functions of microglia
that exist in white as compared to those that occur in gray matter, such as is the case for
macroglia (McKay et al. 2007). The present research is the first study to begin to characterize
microglial phenotypes at the cellular level in both white and gray matter in ASD. The primary
findings of this study demonstrate a significantly high level of expression of insulin-like growth
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factor 1 gene, IGF1, in ACC white matter and a significantly low level of expression of mannose
receptor type 1, MRC1, in ACC gray matter from donors with ASD when compared to typically
developed controls.
IGF1 is a mitogenic factor imperative for fetal brain development and growth. In the
brain, IGF1 encourages the differentiation and maturation of oligodendrocytes, myelination, and
neuronal survival. It is also able to act as an opponent to ROS-related processes by inactivating
mediators that participate in cell death (reviewed by Homolak et al. 2015). In humans, there is
an age-related decline in IGF1 levels and there is increasing evidence that IGF1 expression is
reduced in neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease
(reviewed by Bassil et al. 2014). Interestingly, a case study reported that a 15-year-old boy with
mental retardation had a homozygous partial deletion of the IGF1 gene (Woods et al. 1996).
Likewise, IGF1 knockout mice display postnatal lethality, developmental retardation, defects in
organ systems, and infertility (Liu et al. 2000). A pilot study involving 9 children with PhelanMcDermid syndrome, a highly penetrant cause of ASD, reported an association between three
months of IGF1 treatment and substantial improvement in social impairment and behavior
(Kolevzon et al. 2014). Oddly, reduced levels of IGF1 is associated with an extended lifespan in
invertebrates and rodents (Yang et al. 2005). In fact, it is thought that IGF1 antagonists, used to
decrease IGF1 signaling, could impede cancerous cell proliferation and the process of aging
(reviewed by Bassil et al. 2014). In contrast to the effects of reduced IGF1 action, there is a
significant upregulation of IGF1 in subcortical white matter after traumatic brain injury (TBI) in
male mice, suggesting that sustained IGF1 levels offer neuroprotection after TBI (Madathil et al.
2010). However, IGF1 overexpression may lead to cell death by speeding up the cell cycle and
the process of aging (Yang et al. 2005; reviewed by Bassil et al. 2014). These studies
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demonstrate the importance of IGF1 to normal development and aging. It can be hypothesized
that tight regulation of IGF1 expression in humans is essential to prevent morbidities that are
linked with conditions of deficient or excessive IGF1 expression (Yang et al. 2005).
IGF1 binds tightly with the insulin-like growth factor 1 receptor (IGF-1R), triggering the
auto-phosphorylation of the intracellular β-subunit kinase domain of IGF-1R. This autophosphorylation recruits adaptor proteins and subsequently, activates several pathways such as
the MAP kinase and PI3-kinase/Akt pathways (Moloney et al. 2008). Through the MAP kinase
signaling pathway, the binding of IGF1 to IGF-1R initiates cell proliferation and differentiation
(Conti et al. 2011; Fernandez and Torres-Alemán 2012). Activation of the PI3-kinase pathway
inhibits cellular apoptosis, oxidative stress, and inflammation (Conti et al. 2011; Fernandez and
Torres-Alemán 2012). Both the MAP kinase and PI3-kinase/Akt pathways activate mTOR,
which through increasing the cap-dependent translation initiation complex, can increase mRNA
translation that can influence multiple developmental functions (Levitt et al. 2009).
Interestingly, Faridar and coworkers (2014) reported increased activation of the MAP kinase
pathway in mice with ASD-like social and behavioral deficits (Faridar et al. 2014). The increase
in IGF1 expression in white matter found in the present study could translate to elevated mTOR
activation because the mTOR pathway is downstream of IGF1 signaling. If this is occurring, an
upregulation of mTOR and its activity in individuals with ASD would confirm a hypothesis
made by other researchers that mTOR is in fact upregulated in ASD, causing an increase in
unregulated protein synthesis (Sawicka and Zukin 2012; Wang and Doering 2013; Chen et al.
2014).
The high level of IGF1 expression in ASD donors relative to control donors may reflect a
compensatory mechanism of the brain in response to altered neurotransmission in the ACC, to
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decreased structural integrity of the ACC white matter, or deficits in cognitive processing by
encouraging the proliferation of oligodendrocytes and myelination. Increasing proliferation and
differentiation of oligodendrocytes by IGF1 would in turn potentially myelinate neuronal axons,
increase synchronization between brain areas, and increase white matter structural integrity.
Hence, it is not possible at this point to know whether IGF1 gene expression changes are casual
in the pathology of autism or as a result of cellular processes that are activated to correct deficits
that have their root causes in other pathological mechanisms. With the prevalence of
myelinating oligodendrocytes in the white matter, it is plausible that the demand for IGF1 in the
white matter of ASD individuals may be higher than in the gray matter, consistent with our
findings. Additionally, the increase in IGF1 expression could possibly be compensating for low
IGF-1R levels, in which case, the expression of IGF-1R could be a limiting factor in the efficacy
of IGF1 actions in the CNS (Madathil and Saatman 2015).
While the liver is the principal source of circulating IGF1, IGF1 is also expressed by
neurons, microglia, macrophages, and astrocytes in the CNS (Mascotti et al. 1997; Kettenmann
and Ransom 2013). The main source of IGF1 in the brain remains a mystery; some report that
microglia and macrophages are the main expressers, while others state that neurons
predominantly express IGF1 (Suh et al. 2013; reviewed by Madathil and Saatman 2015).
Because the main source of IGF1 in the CNS remains controversial and the dissection method
that was used in the present work is not specific for a particular cell type, the IGF1 expression
changes found in this study may not be solely expressed by anti-inflammatory microglia. Other
prominent cell types within the white matter, such as astrocytes and oligodendrocytes, could be
the source of the elevated IGF1 expression. Given the fact that neurons do not normally reside in
the white matter, it is highly unlikely the elevated IGF1 expression in ASD is occurring in
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neurons. In fact, we did not observe an elevation of IGF1 expression in ASD in gray matter,
where neurons occur in high numbers.
IGF1 also has the ability to inactivate ROS, suggesting the increase in IGF1 expression
may be indicative of increased pro-inflammatory microglia, and thus ROS, in individuals with
ASD. This theory could only be upheld if IGF1 was in fact, being expressed by antiinflammatory microglia. Moreover, overactive pro-inflammatory microglia in ASD individuals
is not the most convincing hypothesis. One would reason that if pro-inflammatory microglia
were causing chronic inflammation in individuals with ASD, we should have also seen a
significant increase in one or more of the pro-inflammatory genes investigated in this study.
This conclusion leads to the possibility that another cell type (but not neurons) in the CNS is
responsible for the increased levels of IGF1. Despite what is known about IGF1, further
research is required in order to determine the cellular source of the elevated IGF1 expression
levels and the potential role those levels play in the pathology of ASD.
Studies that have attempted to characterize anti-inflammatory microglia have reported
MRC1 as an M2 expressed gene (reviewed by Cherry et al. 2014; Benson et al. 2015; Walker et
al. 2015). CD206, the protein form of MRC1, is a single domain transmembrane receptor that
recognizes mannose, fucose, or N-acetylglucosamine residues on the surface proteins of various
microorganisms such as C. albicans, Leishmania donovani, Mycobacterium tuberculosis,
Pneumocystis carinii, HIV, and Dengue virus (Gazi and Martinez-Pomares 2009; Kerrigan and
Brown 2009). After recognition by CD206, cellular F-actin depolymerizes so that the foreign
material can be engulfed by the cell and digested via the endocytic pathway (reviewed by Gazi
and Martinez-Pomares 2009). While the full functions of MRC1 expression by anti-
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inflammatory microglia in the brain are still unknown, CD206 is important for endocytosis and
pinocytosis (of surrounding fluids in the CNS) (Lively and Schlichter 2012).
In this present study, lower MRC1 expression levels in gray matter in ASD donors were
found as compared to typically developed controls. This finding is novel in ASD research as
there are no existing studies reporting the involvement of the mannose receptor in ASD. One
study found that the expression of the mannose receptor was lower in mouse serum during the
early stages of inflammation, but was upregulated during the later stages of inflammation.
During the later stages of inflammation, the mannose receptor clears inflammatory mediators. In
fact, some inflammatory inducers have been shown to down-regulate the expression of the
mannose receptor, such as LPS and INFγ (Shepherd et al. 1990; Lee et al. 2002). While this is
an interesting connection between the literature and our findings, it is important to point out that
the findings by Lee and coworkers was in serum and not in brain tissue. In this regard, the lower
MRC1 expression levels found by Lee et al. are most likely expressed by macrophages and not
microglia, since microglia are only found in the CNS. Unfortunately, the distinction between
macrophages and microglia in the brain is not clear. While microglia are considered the
“macrophages of the CNS,” macrophages from other locations in the body are able to cross
through the blood brain barrier during an inflammatory response. Additionally, most markers
that are stated to be expressed by M1 and M2 microglia are also expressed by M1 and M2
macrophages. With regards to our results, we are not able to confidently say that the lower
MRC1 expression levels in gray matter were being expressed by anti-inflammatory microglia. If
the ASD donors happen to have elevated levels of pro-inflammatory mediators, it is possible that
the lower MRC1 expression is occurring from macrophages that have migrated into the CNS.
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This reinforces the need, in future studies, to isolate anti-inflammatory microglia and study the
expression of the differentially expressed genes found in this study.
IL1β (encoded by the gene IL1B) is an inflammatory cytokine that can stimulate
inflammation in tissues by activating immune cells in early stages of an immune response
(reviewed by Goines and Ashwood 2013). Piton and coworkers (2008) found an association
between IL1β receptor associated proteins and ASD, while Ashwood and coworkers (2011)
found increased plasma IL1β levels in children with ASD (Piton et al. 2008; Ashwood et al.
2011). It has also been reported that in children with ASD, there is excessive production of IL1β
in response to LPS (reviewed by Goines and Ashwood 2013). In our study, we found no
statistically significant differences in the expression levels of IL1B in white nor gray matter from
ASD compared to control donors; however, we did find high levels of variability in the
expression levels of IL1B in the ASD donors in both matter types. While the variability of IL1B
expression could suggest an increased pro-inflammatory response in some ASD donors, it is
important to consider the cause of donor death. A cause of death such as infection or drowning
may cause in increase in pro-inflammatory cytokines and ROS, thus may not accurately
represent typical cytokine expression levels in ASD (Bierens 2014).
In summary, while we are not able to distinguish the origin of the differential expression
levels for IGF1 and MRC1, we are able to conclude that there is an increase of IGF1 expression
and a decrease of MRC1 expression in the ASD. These findings give strong justification for
future investigations of the specific roles of IGF1, CD206, and pro-inflammatory and antiinflammatory microglia in ASD pathology. The current findings advance ASD research by
providing information for the experimental design to study glia pathology, which could
ultimately lead to the development of novel therapeutic options and advanced diagnostic tools.
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Limitations
While white matter and gray matter were analyzed separately, each homogenate of matter
contained many different CNS cell types such as neurons, astrocytes, oligodendrocytes,
microglia, etc. As noted above, a distinction between these two types of brain matter is the
general lack of neurons in white matter and thus, the enrichment of glia in white matter relative
to gray matter. The anti-inflammatory microglial phenotype is difficult to characterize due to the
lack of anti-inflammatory microglial specific markers. Specifically, when discussing the
significant expression differences of IGF1 and MRC1, it is difficult to decipher the source of
these differential expression levels because they are expressed on a wide array of cells. Reported
M2 microglial phenotypic polarizers (stimulators) IL10, IL4, IL13, TGFβ, TNFα, and INFγ are
released by and activate a variety of CNS cell types such as neurons, astrocytes, pericytes,
dendritic cells, and other immune cells (Feuerstein et al. 1994; Ledeboer et al. 2002; GottfriedBlackmore et al. 2009; Kovac et al. 2011; Gadani et al. 2012; Chhor et al. 2013; Villapol et al.
2013; Benson et al. 2015). Additionally, ARG1 has been reported to be expressed by antiinflammatory microglia in mice, yet it has been debated in the literature to be expressed in
humans. Our study showed low levels of ARG1 expression in ACC white matter and no
statistically significant difference comparing ASD and control donors. Similar to ARG1, other
reported anti-inflammatory microglial makers such as YM1, FIZZ1, Dectin-1, and CD301 have
been observed in animal studies or have been found to be expressed by human M2 macrophages,
but the expression of those genes by human M2 microglia is argued (reviewed by Cherry et al.
2014). Other M2 microglial markers CD163 and CD204 are known to be expressed by antiinflammatory microglia, but are also reported to be expressed by additional cell types, such as
macrophages and monocytes (Holfelder et al. 2011; Prosniak et al. 2013). While it is necessary
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to isolate anti-inflammatory microglia in order to determine its role in ASD pathology, the lack
of definitive markers for the M2 phenotype remains a major limitation of this line of research.
The availability of postmortem ASD brain tissues is also limited, preventing us from
working with larger sample sizes. For all gene expression data, p-values were corrected for the
number of comparisons of dependent variables (gene expressions) using the Holm’s Bonferroni
correction. Corrected p-values indicated no statistically significant difference between ASD and
control donors for all of the genes studied, including IGF1 and MRC1 (Table 6). We attribute
lack of Bonferroni-adjusted significance of IGF1 and MRC1 expression levels to our small
sample size. The immunohistochemistry portion of this study was originally attempted using
frozen BA24 tissue, however; after many attempts with CD206 antibodies, protocol changes, and
negative slide (no primary antibody) optimizations, an immunohistochemical stain for the antiinflammatory mannose receptor was not successful. At the time of the study, we had not
received fixed BA24 tissue, so an immunohistochemical stain on fixed tissue was not feasible.
Additionally, because of the limited availability of tissues, some ASD and control donors were
exposed to medications (Table 2) that might potentially influence the outcomes of this study.
When donors were matched, variation between pairs was reduced as much as possible.
Due to the lack of understanding regarding the anti-inflammatory microglial phenotype,
we decided to first examine four anti-inflammatory microglial markers, in addition to five proinflammatory microglial markers, using punch-dissected white and gray matter. While punchdissections of white and gray matter capture microglia along with various additional cell types
present in the tissue, this approach was ideal for the initial investigation of microglia in ASD.
Specifically capturing microglia via laser capture microdissection methods were limited by time
and financial resources. The decision was made that if significant changes in gene expression
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between ASD and control donors were found in this study, we would then proceed to specifically
capture microglial cells for further analysis.
Finally, an elevation of the expression levels of a gene does not necessarily translate to an
increase in protein levels of the product of that gene. Translation of protein from mRNA is
regulated by a variety of factors. Hence, further research will be required to confirm that
elevated IGF1 or reduced MRC1 mRNA levels translate to elevated IGF1 or reduced MRC1
protein levels. Regardless of whether there is a like change in protein levels for these genes, it is
certain that a difference in gene expression levels (comparing ASD and control donors) implies a
pathological process involving these genes in ASD.

Future Studies
While we are not able to confidently say our findings are specific to microglia, the results
of this study do provide a basis for future investigations using immunohistochemistry to identify
anti-inflammatory microglia and laser capture microdissection to specifically select microglia
from white and gray matter BA24 tissue for further gene expression studies. While the literature
indicates successful immunohistochemical identification of CD206 in fixed brain tissue, the late
arrival of fixed BA24 tissue in our lab did not allow for optimization due to time constraints.
Continuation of this study would begin with the immunohistochemical identification of CD206
in fixed brain tissue and then the explicit capture of anti-inflammatory microglia using laser
capture microdissection. Once anti-inflammatory microglia are captured, the expression of IGF1
in white matter and MRC1 in gray matter can be analyzed to determine if anti-inflammatory
microglia are the source of these differential expression levels. The mentioned methods can also
be used to capture astrocytes as a secondary investigation in the study.
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Increasing the donor sample size and isolating glial cells in ACC white and gray matter
are needed to confirm the differential expression levels of IGF1 and MRC1 identified in ASD in
the present study. This work is currently underway in the laboratory. The gene and protein
expression of IGF-1R is also an imperative aspect to examine. If there is differential expression
of IGF-1R in ASD individuals, it could theoretically affect the efficiency of increased IGF1
levels that are implicated to occur in ASD by the result of this study. Furthermore, studying the
individual components of the mTOR pathway (downstream of IGF1 signaling) in individuals
with ASD is a necessary step to further ASD research. Identifying potential abnormalities in a
specific component(s) of the mTOR pathway could provide clues for the development of
therapeutic agents.
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APPENDICES
APPENDIX A: ABBREVIATIONS
Abbreviation
ACC
ADI-R
ARG1
ASD
BA24
CD68
CNS
CNV
DAB
DSM
EMP
FMR1
fMRI
GAPDH
GM
HLA-DRA
ID
IGF1
IGF-1R
IL1B
iNOS
Kb
LPS
M1
M2
MRC1
mTOR
NFM1
NHS
NO
NOS2
PMI
PPARG
PTEN
PTGS2
qPCR
RIN

Definition
anterior cingulate cortex
Autism Diagnostic Interview-Revised
arginase 1
autism spectrum disorder
Brodmann area 24
cluster of differentiation 68
central nervous system
copy number variation
3,3'-Diaminobenzidine tetrahydrochloride
Diagnostic and Statistical Manual
erythromyeloid progenitor
fragile X mental retardation 1
functional magnetic resonance imaging
glyceraldehyde-3-phosphate dehydrogenase
gray matter
human leukocyte antigen-antigen D related, alpha chain
identification number
insulin-like growth factor 1
Insulin-like growth factor 1 receptor
interleukin 1 beta
inducible nitric oxide synthase
kilobase
lipopolysaccharide
pro-inflammatory/classically activated/neurotoxic
anti-inflammatory/alternatively activated/neuroprotective
mannose receptor type 1
mammalian target of rapamycin
Neurofibromatosis 1
normal horse serum
nitric oxide
nitric oxide synthase 2, inducible
post-mortem interval
peroxisome proliferator-activated receptor gamma
phosphatase and tensin homolog
prostaglandin-endoperoxide synthase 2
quantitative real-time polymerase chain reaction
RNA integrity number
82

ROS
SNP
TATA
T1D
TLR4
TSC1/2
WM

reactive oxygen species
single nucleotide polymorphism
TATA-box binding protein
type 1 diabetes
toll-like receptor 4
tuberous sclerosis complexes 1 and 2
white matter
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APPENDIX B: PRIMER SEQUENCES OF REFERENCE AND MARKER GENES
Target or
Reference
Gene

Genbank Accession
Number

Primer Sequence

PCR Product
Size (bp)

ARG1 (set A)

NM_001244438,
NM_000045

(f) 5'-GGT GAC TCC CTG TAT ATC TGC CAA G-3'
(r) 5'-GCC AAT TCC TAG TCT GTC CAC TTC AG3'

136

CD68

NM_001040059,
NM_001251

Not available (Qiagen)

73

GAPDH

NM_002046

(f) 5'-TGC ACC ACC AAC TGC TTA GC-3'
(r) 5'-GGC ATG GAC TGT GGT CAT GAG-3'

87

HLA-DRA
(set C)

NM_019111

(f) 5'-GTG GAC AAA GCC AAC CTG GAA ATC-3'
(r) 5'-GGA CGT TGG GCT CTC TCA GTT C-3'

121

IGF1
(set B)

NM_001111283,
NM_001111284,
NM_000618

(f) 5'-TCC CTT TCA AGC CAC CCA TTG A-3'
(r) 5'-AGT GTG TTT AGC AGC GGG TAC AAG-3'

115

IL1B

NM_000576,
XM_006712496

Not available (Qiagen)

117

MRC1

NM_001009567,
NM_002438

Not available (Qiagen)

86

NOS2

NM_006554 (1399
bp)

(f) 5'-GGC TGT CGT TGA GAT CAA CAT TGC
TGT G-3'
(r) 5'-CGG GAC CGG TAT TCA TTC TGC ATG
TAC T-3'

123

PPARϒ

NR_027850 (1603
bp)

(f) 5'-TCT CAA ACG AGA GTC AGC CT-3'
(r) 5'-GAG TGG GAG TGG TCT TCC ATT AC-3'

120

PTGS2
(set B)

XM_006712199
(1229 bp)

(f) 5'-CTC TGG CTA GAC AGC GTA AAC T-3'
(r) 5-CCG TAG ATG CTC AGG GAC TTG-3'

143

TATA

NM_001172085,
NM_003194

Not available (Qiagen)

132
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